Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery
Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty a...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English English |
Published: |
Springer Nature , BioMed Central Ltd
2022
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/38380/1/Marcucci%202022.pdf http://ir.unimas.my/id/eprint/38380/2/Marcucci%202022%20Appendix%2010.docx http://ir.unimas.my/id/eprint/38380/ https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05992-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.unimas.ir.38380 |
---|---|
record_format |
eprints |
spelling |
my.unimas.ir.383802022-04-22T02:54:09Z http://ir.unimas.my/id/eprint/38380/ Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery Samuel Ern Hung, Tsan Marcucci, Maura Painter, Thomas W. Conen, David Leslie, Kate Lomivorotov, Vladimir Sessler, David Chan, Matthew T. V R Medicine (General) RD Surgery Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. Springer Nature , BioMed Central Ltd 2022 Article PeerReviewed text en http://ir.unimas.my/id/eprint/38380/1/Marcucci%202022.pdf text en http://ir.unimas.my/id/eprint/38380/2/Marcucci%202022%20Appendix%2010.docx Samuel Ern Hung, Tsan and Marcucci, Maura and Painter, Thomas W. and Conen, David and Leslie, Kate and Lomivorotov, Vladimir and Sessler, David and Chan, Matthew T. V (2022) Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials, 23 (101). pp. 1-12. ISSN 1745-6215 https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05992-1 DOI:10.1186/s13063-021-05992-1 |
institution |
Universiti Malaysia Sarawak |
building |
Centre for Academic Information Services (CAIS) |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Malaysia Sarawak |
content_source |
UNIMAS Institutional Repository |
url_provider |
http://ir.unimas.my/ |
language |
English English |
topic |
R Medicine (General) RD Surgery |
spellingShingle |
R Medicine (General) RD Surgery Samuel Ern Hung, Tsan Marcucci, Maura Painter, Thomas W. Conen, David Leslie, Kate Lomivorotov, Vladimir Sessler, David Chan, Matthew T. V Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
description |
Background: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated
with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with
the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac
surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e.,
most patients continue their antihypertensive medications throughout the perioperative period and intraoperative
mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve
perioperative outcomes. |
format |
Article |
author |
Samuel Ern Hung, Tsan Marcucci, Maura Painter, Thomas W. Conen, David Leslie, Kate Lomivorotov, Vladimir Sessler, David Chan, Matthew T. V |
author_facet |
Samuel Ern Hung, Tsan Marcucci, Maura Painter, Thomas W. Conen, David Leslie, Kate Lomivorotov, Vladimir Sessler, David Chan, Matthew T. V |
author_sort |
Samuel Ern Hung, Tsan |
title |
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
title_short |
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
title_full |
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
title_fullStr |
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
title_full_unstemmed |
Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
title_sort |
rationale and design of the perioperative ischemic evaluation-3 (poise-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery |
publisher |
Springer Nature , BioMed Central Ltd |
publishDate |
2022 |
url |
http://ir.unimas.my/id/eprint/38380/1/Marcucci%202022.pdf http://ir.unimas.my/id/eprint/38380/2/Marcucci%202022%20Appendix%2010.docx http://ir.unimas.my/id/eprint/38380/ https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05992-1 |
_version_ |
1731229850926055424 |
score |
13.18916 |